title: FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
abstract: OBJECTIVE
  Allelic variants of fucosyltransferases 2 and 3 (FUT2/3) influence serum levels of CA19-9, a screening parameter commonly used for detection of biliary malignancy in PSC. We aimed at improving diagnostic accuracy of CA19-9 by determining the impact of FUT2/3 genotypes.
  
  
  METHODS
  CA19-9 levels were measured in 433 PSC patients, 41 of whom had biliary malignancy. Genotypes for FUT3 and FUT2 were used to assign patients to one of three groups: A, no FUT3 activity regardless of FUT2 activity; B, both FUT2 and FUT3 activity and C, no FUT2 activity without loss of FUT3 activity. Group-specific cut-off values were determined by Youden's index.
  
  
  RESULTS
  The median CA19-9 values of cancer-free patients were significantly different (p<0.001) in Groups A (2.0U/ml), B (17.0U/ml), and C (37.0U/ml). Biliary malignancy patients in Groups B and C had significantly higher CA19-9 values than cancer-free patients (p<0.001). The optimal cut-off, as determined by ROC analysis, for all patients was 88.5U/ml. Optimal cut-off values in Groups A, B, and C were 4.0U/ml, 74.5U/ml, and 106.8U/ml, respectively. Use of these values improved sensitivity of CA19-9 in Groups B and C. Further, use of group-dependent cut-off values with 90% sensitivity resulted in a 42.9% reduction of false positive results.
  
  
  CONCLUSIONS
  Use of FUT2/3 genotype-dependent cut-off values for CA19-9 improved sensitivity and reduced the number of false positive results.
authors: Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany.
authors: Andreas
authors: A
authors: Wannhoff
authors: Johannes Roksund
authors: JR
authors: Hov
authors: Trine
authors: T
authors: Folseraas
authors: Christian
authors: C
authors: Rupp
authors: Kilian
authors: K
authors: Friedrich
authors: Jarl Andreas
authors: JA
authors: Anmarkrud
authors: Karl Heinz
authors: KH
authors: Weiss
authors: Peter
authors: P
authors: Sauer
authors: Peter
authors: P
authors: Schirmacher
authors: Kirsten Muri
authors: KM
authors: Boberg
authors: Wolfgang
authors: W
authors: Stremmel
authors: Tom Hemming
authors: TH
authors: Karlsen
authors: Daniel Nils
authors: DN
authors: Gotthardt
mesh_terms: D000328:Adult; D001650:Bile Duct Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D001653:Bile Ducts, Intrahepatic; D018395:CA-19-9 Antigen / Q000097:blood*; D018281:Cholangiocarcinoma / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D015209:Cholangitis, Sclerosing / Q000150:complications*; D005260:Female; D005647:Fucosyltransferases / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies; D000097631:Galactoside 2-alpha-L-fucosyltransferase
chemical_list: D018395:CA-19-9 Antigen; D005647:Fucosyltransferases; D000097631:Galactoside 2-alpha-L-fucosyltransferase; C019818:3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase
keywords: AASLD; AUC; American Association for the Study of Liver Diseases; CA19-9; CCA; Cholangiocarcinoma; EASL; European Association for the Study of the Liver; FUT2; FUT3; Fucosyltransferase 2; Fucosyltransferase 3; GBCA; Gallbladder carcinoma; HD; Heidelberg; IBD; IQR; LT; MELD; Model of End-Stage Liver Disease; NPV; O; Oslo; PPV; PSC; Primary sclerosing cholangitis; ROC; SNP; WGA; area under the curve; carbohydrate antigen 19-9; cholangiocarcinoma; fucosyltransferase 2; fucosyltransferase 3; gallbladder carcinoma; inflammatory bowel disease; inter-quartile range; liver transplantation; negative predictive value; positive predictive value; primary sclerosing cholangitis; receiver operating characteristic; single-nucleotide polymorphism; whole-genome amplified